Meta-analysis of the Efficacy and Safety of Sativex (nabiximols), on Spasticity in People with Multiple Sclerosis
Overview
Affiliations
Objective: To determine the efficacy of Sativex (USAN: nabiximols) in the alleviation of spasticity in people with multiple sclerosis.
Methods: The results from three randomized, placebo-controlled, double-blind parallel group studies were combined for analysis.
Patients: 666 patients with multiple sclerosis and spasticity.
Measures: A 0-100 mm Visual Analogue Scale (VAS, transformed to a 0-10 scale) or a 0-10 Numerical Rating Scale (0-10 NRS) was used to measure spasticity. Patients achieving a > or =30% improvement from baseline in their spasticity score were defined as 'responders'. Global impression of change (GIC) at the end of treatment was also recorded.
Results: The patient populations were similar. The adjusted mean change of the numerical rating scale from baseline in the treated group was -1.30 compared with -0.97 for placebo. Using a linear model, the treatment difference was -0.32 (95% CI -0.61, -0.04, p = 0.026). A statistically significant greater proportion of treated patients were responders (odds ratio (OR) = 1.62, 95% CI 1.15, 2.28; p = 0.0073) and treated patients also reported greater improvement: odds ratio 1.67 (95% CI 1.05, 2.65; p = 0.030). High numbers of subjects experienced at least one adverse event, but most were mild to moderate in severity and all drug-related serious adverse events resolved.
Conclusion: The meta-analysis demonstrates that nabiximols is well tolerated and reduces spasticity.
Therapeutic use of medical Cannabis in neurological diseases: a clinical update.
Hidding U, Mainka T, Buhmann C J Neural Transm (Vienna). 2023; 131(2):117-126.
PMID: 38015317 PMC: 10791790. DOI: 10.1007/s00702-023-02719-1.
Voicu V, Brehar F, Toader C, Covache-Busuioc R, Corlatescu A, Bordeianu A Biomolecules. 2023; 13(9).
PMID: 37759788 PMC: 10526757. DOI: 10.3390/biom13091388.
Molecular and Cellular Mechanisms of Action of Cannabidiol.
Martinez Naya N, Kelly J, Corna G, Golino M, Abbate A, Toldo S Molecules. 2023; 28(16).
PMID: 37630232 PMC: 10458707. DOI: 10.3390/molecules28165980.
Kleiner D, Horvath I, Bunduc S, Gergo D, Lugosi K, Fehervari P Curr Neuropharmacol. 2023; 21(12):2505-2515.
PMID: 37519000 PMC: 10616923. DOI: 10.2174/1570159X21666230727094431.
Rainka M, Aladeen T, Mattle A, Lewandowski E, Vanini D, McCormack K Int J MS Care. 2023; 25(3):111-117.
PMID: 37250194 PMC: 10211357. DOI: 10.7224/1537-2073.2022-006.